文献速递前列腺癌

动态对比增强磁共振成像改善前列腺病灶分类:靶向穿刺病理结果研究

Dynamic Contrast Enhanced Magnetic Resonance Imaging Improves Classification of Prostate Lesions: A Study of Pathological Outcomes on Targeted Prostate Biopsy.
PubMed 文献 · J Urol · 2017-07-11

研究纳入290例无前列腺癌病史患者共389个外周带DWI评分3或4病灶,评估DCE成像能否将病灶分入有临床意义的病理分组。结果显示DWI评分3病灶若DCE阳性,其Grade Group≥2癌症检出率更高(21% vs 8.9%),在既往系统穿刺阴性患者中差异最明显(28% vs 5.0%)。

要点

  • DWI评分3外周带病灶中,DCE阳性者Grade Group≥2检出率21%,DCE阴性者8.9%(p<0.03)。
  • 既往系统穿刺阴性患者中,DCE阳性组Grade Group≥2检出率28% vs DCE阴性组5.0%(p<0.001)。
  • 无既往穿刺患者中DCE阳性与阴性组Grade Group≥2检出率无显著差异(16% vs 12%,p=0.5)。

核心结论

  • DWI评分3的外周带病灶若DCE T1加权成像阳性,更可能为临床显著癌(Grade Group≥2),该差异在既往系统穿刺阴性患者中最明显。
  • 在既往系统穿刺阴性患者中,将DCE序列纳入多参数磁共振成像可实现最佳病灶风险分层。

研究设计与样本

  • 回顾性识别无前列腺癌病史、接受多参数磁共振-经直肠超声融合靶向穿刺、外周带病灶DWI评分为3或4的患者。
  • 共纳入290例患者的389个外周带DWI评分3或4病灶,分为三组:第1组DWI评分3/无强化/PI-RADS 3,第2组DWI评分3/强化/PI-RADS 4,第3组DWI评分4/PI-RADS 4。
  • 测量每组病灶Grade Group≥2病理检出率,并按既往系统穿刺阴性与否进行亚组分析。

主要发现

  • 第1、2、3组病灶穿刺Grade Group≥2癌症检出率分别为8.9%、21%、36.5%(p<0.03)。
  • 既往系统穿刺阴性患者中,第2组Grade Group≥2检出率高于第1组(28% vs 5.0%,p<0.001)。
  • 无既往穿刺患者中,第2组与第1组Grade Group≥2检出率无显著差异(16% vs 12%,p=0.5)。
  • 穿刺初治亚组中,第3组Grade Group≥2检出率高于第2组(46% vs 16%,p=0.001)。
  • 既往系统穿刺阴性患者中,第3组与第2组Grade Group≥2检出率相似(27% vs 28%,p=0.9)。

关键数值与推荐

  • PI-RADS第2版规定DWI评分3的外周带病灶应根据DCE成像分类为PI-RADS 3(DCE阴性或无强化)或PI-RADS 4(DCE阳性或强化)。
  • 第1组:DWI评分3/无强化/PI-RADS 3;第2组:DWI评分3/强化/PI-RADS 4;第3组:DWI评分4/PI-RADS 4。

临床怎么用

  • 作者结论认为,在既往系统穿刺阴性的患者中,将DCE序列纳入多参数磁共振成像可实现最佳病灶风险分层。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: PI-RADS™, version 2 stipulates that dynamic contrast enhanced imaging should be used to classify diffusion-weighted imaging score 3 peripheral zone lesions as PI-RADS score 3 (dynamic contrast enhanced imaging negative or nonenhancing) or 4 (dynamic contrast enhanced imaging positive or enhancing). However, to our knowledge it is unknown whether dynamic contrast enhanced imaging separates lesions into clinically meaningful pathological groups. We examined whether dynamic contrast enhanced imaging would improve the detection of clinically significant cancer. MATERIALS AND METHODS: We identified patients without a prior diagnosis of prostate cancer who underwent multiparametric magnetic resonance imaging-transrectal ultrasound fusion targeted biopsy of peripheral zone lesions with a diffusion-weighted imaging score of 3 or 4. Each lesion was grouped into 1 of 3 classifications, including group 1-diffusion-weighted imaging score 3/nonenhancing/PI-RADS score 3, group 2-diffusion-weighted imaging score 3/enhancing/PI-RADS score 4 or group 3-diffusion-weighted imaging score 4/PI-RADS score 4. We measured the rate of grade group 2 or greater pathology detected for each lesion group with subgroup analyses in patients with vs without prior negative systematic biopsy. RESULTS: We identified a total of 389 peripheral zone diffusion-weighted imaging score 3 or 4 lesions in 290 patients. The rate of grade group 2 or greater cancer on biopsy for group 1, 2 and 3 lesions was 8.9%, 21% and 36.5%, respectively (p <0.03). The rate of grade group 2 or greater pathology was higher in group 2 than group 1 lesions in patients with prior negative systematic prostate biopsy (28% vs 5.0%, p <0.001) but not in those without such a biopsy (16% vs 12%, p = 0.5). Group 3 lesions had a higher rate of grade group 2 or greater cancer than group 2 lesions in the biopsy naïve subgroup (46% vs 16%, p = 0.001). However, the rates were similar in patients with prior negative systematic prostate biopsy (27% vs 28%, p = 0.9). CONCLUSIONS: Diffusion-weighted imaging score 3 peripheral zone lesions were more likely to be clinically significant cancer (grade group 2 or greater) if they were dynamic contrast enhanced T1-weighted imaging positive. That was most apparent in patients with a prior negative systematic prostate biopsy. In such patients including a dynamic contrast enhanced sequence in multiparametric magnetic resonance imaging allowed for optimal lesion risk stratification.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Druskin SC, Ward R, Purysko AS, et al. Dynamic Contrast Enhanced Magnetic Resonance Imaging Improves Classification of Prostate Lesions: A Study of Pathological Outcomes on Targeted Prostate Biopsy. J Urol. 2017. PMID: 28709889. doi:10.1016/j.juro.2017.07.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。